Later-line therapies after failure of standard treatments for advanced colorectal and non-colorectal cancer patients are limited. Mismatch repair (MMR) deficiency or microsatellite instability-high (MSI-H) played a role of positive predictive factor, which had been documented after the pembrolizumab and nivolumab trial were reported, for PD-1 blockade monotherapy in patients with advanced colorectal and non-colorectal cancers.~In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy.~For colorectal cancer participants, who are required to have been previously treated with standard therapies or refuse standard of care therapy. For other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy.~For colorectal cancer participants, who are required to have been previously treated with standard therapies or refuse standard therapy, other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.